Stem Cell Mobilization

PROCEDURE4 trials

Sponsors

National Heart, Lung, and Blood Institute (NHLBI), Massachusetts General Hospital, Dana-Farber Cancer Institute

Conditions

Acute Myelogenous LeukemiaCoronary Artery DiseaseLymphomaMultiple Myeloma

Phase 1

Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization.

CompletedNCT00299780

Massachusetts General HospitalAcute Myelogenous Leukemia, Lymphoma, Multiple Myeloma

Start: 2004-07-31End: 2007-04-30Target: 12Updated: 2007-04-24

Phase 2

Stem Cell Mobilization to Treat Chest Pain and Shortness of Breath in Patients With Coronary Artery Disease

CompletedNCT00043628

National Heart, Lung, and Blood Institute (NHLBI)Coronary Artery Disease

Start: 2002-08-31End: 2005-02-28Target: 35Updated: 2008-03-04

Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

CompletedNCT02375555

Dana-Farber Cancer InstituteMultiple Myeloma

Start: 2015-05-07End: 2024-01-26Updated: 2024-10-01

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

CompletedNCT02441686

Dana-Farber Cancer InstituteMultiple Myeloma

Start: 2015-12-31End: 2025-10-31Updated: 2026-01-13

Related Papers

Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma

American Journal of Hematology2022-02-084 citations

An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma.

Journal of Clinical Oncology2017-05-2018 citations